Krishna Institute of Medical Sciences Limited
Momentum (86/100) does the heavy lifting; valuation (0/100) is the drag.
ExpensiveOvervaluedOur blended model reads Krishna Institute of Medical Sciences Limited as a Sell at 32/100. On 131.6x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 6% below its 52-week high of ₹850.65 and 37% above the low of ₹582.1. Financial health scores 83/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹827.19 implies about 4% upside across 16 analysts. It clears 4 of 13 investability checks, with durability 22, valuation 0 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹319.2.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-6.19% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell32Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.7%
- Fail: Low debt (D/E < 0.5): 1.66x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 35%
- Fail: Earnings growing: -58%
- Fail: Net margin ≥ 10%: 6.2%
- Fail: Current ratio > 1.5: 0.76
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.32
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter41.7%
- Institutions38.3%
- Public & other19.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Financially solid — Altman Z 4.32.
Opportunities
- Revenue growing (35% YoY).
Bear case
Weaknesses
- High debt relative to equity.
- Weak Piotroski score (3/9).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Krishna Institute of Medical Sciences Limited
KIMS Hospitals operates a network of medical facilities in India offering specialized services across multiple disciplines including cardiology, orthopedics, neurosurgery, oncology, organ transplantation, gastroenterology, nephrology, obstetrics and gynecology, pediatrics, and emergency care, among others.
Krishna Institute of Medical Sciences Limited — frequently asked questions
Is Krishna Institute of Medical Sciences Limited a buy, hold or sell?
StocksWizard currently rates Krishna Institute of Medical Sciences Limited (KIMS) a Sell, based on a blended score of 32/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Krishna Institute of Medical Sciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Krishna Institute of Medical Sciences Limited's fair value at about ₹399, versus a current price of ₹798 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Krishna Institute of Medical Sciences Limited financially healthy?
Krishna Institute of Medical Sciences Limited scores 83/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Krishna Institute of Medical Sciences Limited's share price performed?
Krishna Institute of Medical Sciences Limited is up 20% over three months, and last traded at ₹798. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.